Impact of peptide transporter 1 on the intestinal absorption and pharmacokinetics of valacyclovir after oral dose escalation in wild-type and PepT1 knockout mice

Drug Metabolism and Disposition

Volumn 41, Issue 10, 2013, Pages 1867-1874

  Yang, Bei ^a   Hu, Yongjun ^a   Smith, David E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; DRUG METABOLITE; PEPTIDE TRANSPORTER 1; TRITIUM; VALACICLOVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG TISSUE LEVEL; FEMALE; GENOTYPE; IN VIVO STUDY; INTESTINE ABSORPTION; ISOTOPE LABELING; KNOCKOUT MOUSE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SPECIES COMPARISON; SYSTEMIC CIRCULATION; WILD TYPE;

ACYCLOVIR; ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; INTESTINAL ABSORPTION; INTESTINES; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, KNOCKOUT; SYMPORTERS; TISSUE DISTRIBUTION; VALINE;

EID: 84884694215     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.052597     Document Type: Article

References (32)

1. Anand BS, Katragadda S, and Mitra AK (2004) Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. J Pharmacol Exp Ther 311:659-667. (Pubitemid 39391553)
2. Balimane P and Sinko P (2000) Effect of ionization on the variable uptake of valacyclovir via the human intestinal peptide transporter (hPepT1) in CHO cells. Biopharm Drug Dispos 21:165-174. (Pubitemid 32115041)
3. Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, and Sinko PJ (1998) Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun 250:246-251. (Pubitemid 28463863)
4. Bhardwaj RK, Herrera-Ruiz D, Eltoukhy N, Saad M, and Knipp GT (2006) The functional evaluation of human peptide/histidine transporter 1 (hPHT1) in transiently transfected COS-7 cells. Eur J Pharm Sci 27:533-542. (Pubitemid 43363344)
5. Bhardwaj RK, Herrera-Ruiz D, Sinko PJ, Gudmundsson OS, and Knipp G (2005) Delineation of human peptide transporter 1 (hPepT1)-mediated uptake and transport of substrates with varying transporter affinities utilizing stably transfected hPepT1/Madin-Darby canine kidney clones and Caco-2 cells. J Pharmacol Exp Ther 314:1093-1100. (Pubitemid 41205973)
6. Brandsch M, Knütter I, and Bosse-Doenecke E (2008) Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol 60:543-585. (Pubitemid 351589044)
7. Chen ML (1992) An alternative approach for assessment of rate of absorption in bioequivalence studies. Pharm Res 9:1380-1385.
8. Chen ML, Lesko L, and Williams RL (2001) Measures of exposure versus measures of rate and extent of absorption. Clin Pharmacokinet 40:565-572. (Pubitemid 32758579)
9. Ganapathy ME, Huang W, Wang H, Ganapathy V, and Leibach FH (1998) Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun 246:470-475. (Pubitemid 28412626)
10. Ganapathy V, Gupta N, and Martindale RG (2006) Protein digestion and absorption, in Physiology of the Gastrointestinal Tract, 4th ed (Johnson LR ed) pp 1667-1692, Elsevier, Burlington, MA.
11. Guo A, Hu P, Balimane PV, Leibach FH, and Sinko PJ (1999) Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther 289:448-454. (Pubitemid 29156062)
12. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadée W, and Amidon GL (1998) 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res 15:1154-1159. (Pubitemid 28401703)
13. Hatanaka T, Haramura M, Fei YJ, Miyauchi S, Bridges CC, Ganapathy PS, Smith SB, Ganapathy V, and Ganapathy ME (2004) Transport of amino acid-based prodrugs by the Na+- and Cl(-)-coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther 308:1138-1147. (Pubitemid 38263991)
14. Hu Y, Smith DE, Ma K, Jappar D, Thomas W, and Hillgren KM (2008) Targeted disruption of peptide transporter Pept1 gene in mice significantly reduces dipeptide absorption in intestine. Mol Pharm 5:1122-1130.
15. Jappar D, Wu SP, Hu Y, and Smith DE (2010) Significance and regional dependency of peptide transporter (PEPT) 1 in the intestinal permeability of glycylsarcosine: in situ single-pass perfusion studies in wild-type and Pept1 knockout mice. Drug Metab Dispos 38:1740-1746.
16. Landowski CP, Sun D, Foster DR, Menon SS, Barnett JL, Welage LS, Ramachandran C, and Amidon GL (2003) Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther 306:778-786. (Pubitemid 36886180)
17. McConnell EL, Basit AW, and Murdan S (2008) Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol 60:63-70.
18. Ocheltree SM, Shen H, Hu Y, Keep RF, and Smith DE (2005) Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther 315:240-247. (Pubitemid 41380517)
19. Ormrod D and Goa K (2000) Valaciclovir: a review of its use in the management of herpes zoster. Drugs 59:1317-1340. (Pubitemid 30410147)
20. Phan DD, Chin-Hong P, Lin ET, Anderle P, Sadee W, and Guglielmo BJ (2003) Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor. Antimicrob Agents Chemother 47:2351-2353. (Pubitemid 36753601)
21. Posada MM and Smith DE (2013a) Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. Pharm Res 30:1017-1025.
22. Posada MM and Smith DE (2013b) In vivo absorption and disposition of cefadroxil after escalating oral doses in wild-type and PepT1 knockout mice. Pharm Res [Epub ahead of print].
23. Rubio-Aliaga I and Daniel H (2008) Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica 38:1022-1042.
24. Shen H, Ocheltree SM, Hu Y, Keep RF, and Smith DE (2007) Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice. Drug Metab Dispos 35:1209-1216. (Pubitemid 46956444)
25. Sinko PJ and Balimane PV (1998) Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm Drug Dispos 19:209-217. (Pubitemid 28218415)
26. Smith DE, Clémençon B, and Hediger MA (2013) Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. Mol Aspects Med 34:323-336.
27. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, and Posner J (1995) Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 39:2759-2764.
28. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, and Endou H (2002) Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 300:918-924. (Pubitemid 34164996)
29. Tsume Y, Hilfinger JM, and Amidon GL (2008) Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm 5:717-727.
30. Varma MV, Ambler CM, Ullah M, Rotter CJ, Sun H, Litchfield J, Fenner KS, and El-Kattan AF (2010) Targeting intestinal transporters for optimizing oral drug absorption. Curr Drug Metab 11:730-742.
31. Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, and Smiley ML (1993) Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 54:595-605.
32. Yang B and Smith DE (2013) Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. Drug Metab Dispos 41:608-614.